Concepedia

Publication | Closed Access

Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors

DOI

244

Citations

29

References

2005

Year

Jean L. Grem, Geraldine Morrison, Xiao-Du Guo, Elizabeth B. Agnew, Chris H. Takimoto, Rebecca R. Thomas, Éva Szabó, Louise B. Grochow, Frank Grollman, J. Michael Hamilton,
Journal of Clinical Oncology

Abstract

17-AAG 40 mg/m(2) (median dose, 70 mg) was well tolerated when given daily for 5 days every 3 weeks.

References

YearCitations

Page 1